Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
Dove Medical Press
... the effect of initial intravitreal ranibizumab injection on visual acuity (VA) and central macular thickness (CMT) for the treatment of macular edema (ME) with and without serous retinal detachment (SRD) secondary to branch retinal vein occlusion ...


Retinal Vein Occlusion Market Rising Demand Seen in Healthcare ...
Medgadget (blog)
Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

and more »

Nasdaq

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD
Nasdaq
... other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Relationship between vascular endothelial growth factor and macular edema in retinal vein branch obstruction
Dove Medical Press
Purpose: Vascular endothelial growth factor (VEGF) plays an important role in branch retinal vein occlusion (BRVO) with cystoid macular edema (CME). Monitoring changes in VEGF is crucial for evaluating treatment but requires vitreous or aqueous humor ...


Retinal Vein Occlusion Market to Perceive Superior Growth with CAGR of 11.2% | By Types Branch Retinal Artery ...
Digital Journal
Retinal Vein Occlusion Market Report include on MarketReseacrhFuture.com with Extensive Study. The report aims to provide an overview of Retinal Vein Occlusion Market Report. Detail analysis on possible segments and sub segments of the market.


Nasdaq

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
Nasdaq
... neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion, and macular edema following branch retinal ...
Intl Fcstone Inc. Buys Shares of 674 Regeneron Pharmaceuticals Inc (REGN)Fairfield Current

all 14 news articles »

BioSpace (press release) (blog)

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a ...
BioSpace (press release) (blog)
Outside the U.S., Lucentis is approved in more than 120 countries to treat adult patients with wet AMD, for the treatment of visual impairment due to DME, due to macular edema secondary to both branch retinal vein occlusion (BRVO), central retinal vein ...

and more »

Fairfield Current

Massachusetts Financial Services Co. MA Has $61.08 Million Holdings in Regeneron Pharmaceuticals Inc (NASDAQ ...
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks

all 88 news articles »

Nisa Investment Advisors LLC Has $6.40 Million Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Baseball Daily Digest
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Nasdaq
... an intravitreal anti-VEGF agent may result in earlier, superior visual acuity outcome as compared to monthly injections of an intravitreal anti-VEGF alone in newly diagnosed branch retinal vein occlusion ("BRVO") and central retinal vein occlusion ...

and more »

XNewsPress

Regeneron Pharmaceuticals (REGN) Releases Earnings Results
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
BeiGene launches late-stage study of tislelizumab in first-line lung cancerSeeking Alpha
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Replimune set for $101M IPOSeeking Alpha
Schaeffers Research
all 74 news articles »

MD Magazine

DRIL Presence Predictive of VA Improvement in Patients with Macular Edema, RVO
MD Magazine
... during treatment with anti-vascular endothelial growth factor (anti-VEGF), can be a prognostic indicator for improvement in Early Treatment Diabetic Retinopathy Study (ETDRS) score in patients with macular edema secondary to retinal vein occlusion ...


Plains Ledger

Global Placenta Growth Factor Market 2018 – Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd ...
Plains Ledger
Further the research study is segmented by Application such as :- Branch Retinal Vein Occlusion, Myopia, Neovascular Glaucoma, Others. The research report will enrich your decision-making capability by providing you. 1. Market share evaluations for the ...


Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Massachusetts Financial Services Co. MA
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Replimune set for $101M IPOSeeking Alpha

all 102 news articles »

Regeneron Pharmaceuticals (REGN) Set to Announce Quarterly Earnings on Wednesday
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Placenta Growth Factor Market: Top 20 Countries data, Growth Factors, Industry Overview, Applications, Regional ...
Depositor Money
On the basis on the end users/applications, Placenta Growth Factor market report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including: Branch Retinal Vein ...

and more »

News Oracle

Regeneron Pharmaceuticals Inc (REGN) Director Sells $720000.00 in Stock
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks

all 122 news articles »

Retinal Vein Occlusion Therapeutics Market Facts, Figures and Analytical Insights, Forecast 2015 – 2021
364Analyze.com (press release)
The RVO is mainly of two types based on the anatomy of the vein occlusion. The two types are branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The BRVO occurs when the vein in the distal retinal system gets occluded ...


IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Stonebridge Capital Management Inc. Has $902000 Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Placenta Growth Factor Market Key Players, Industry Overview, Supply Chain And Analysis To 2017-2022
Daily Journal Now (blog)
The Placenta Growth Factor Market report offers a detailed Outlook and future prospects of the Placenta Growth Factor Industry. The Placenta Growth Factor Market report analyses major information that helps Industry experts, analysts and business ...

and more »

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central ...

and more »

Amalgamated Bank Purchases 813 Shares of Regeneron Pharmaceuticals Inc (REGN)
Marea Informative (blog)
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Prentiss Smith & Co. Inc. Decreases Holdings in Regeneron Pharmaceuticals Inc (REGN)
Baseball Daily Digest
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular ...
Dove Medical Press
Poorer final vision was associated with poorer baseline BCVA and diagnosis of central retinal vein occlusion after adjustment for age and sex (p<0.001 and 0.012, respectively). Significant elevation of IOP was noted at 3 months in the PSTA group, but ...


Bel Marra Health

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment
Bel Marra Health
Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each sufferer. There are some cases where a person can recover from BRVO. Here we look at the ...


Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related ...
Dove Medical Press
... short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO).


Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


Retinal Vein Occlusion Market 2018 Global Industry Analysis, Opportunities and Forecast to 2023
Digital Journal
Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two types, namely, Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO). BRVO is ...

» Load more